Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial
Launched by UNIVERSITY OF MICHIGAN · Jan 3, 2022
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Overdiagnosis of ventilator-associated pneumonia (VAP) is common among mechanically-ventilated patients and contributes to antibiotic overuse and the generation of multidrug resistant organisms within intensive care units (ICUs). Identification of interventions that safely and effectively lower VAP overdiagnosis and antibiotic overuse are important for antimicrobial stewardship programs. Antibiotic stewardship interventions targeting VAP have heretofore focused on therapeutic interventions-antibiotic de-escalation or discontinuation-in established VAP cases, but have not leveraged intervent...
Gender
ALL
Eligibility criteria
- Inclusion Criteria Patients included:
- • All patients hospitalized within the Michigan Medicine Cardiac Care Unit (CCU, 7D) and the Michigan Medicine Critical Care Medicine Unit (CCMU, 6D)
- Exclusion Criteria Patients included:
- * For the study intervention requiring performance of bronchoalveolar lavage rather than endotracheal aspirate for respiratory culture collection, the following are exclusion criteria for performance of bronchoalveolar lavage:
- • international normalized ratio (INR)\>2,
- • platelet count \<50,
- • gross blood in endotracheal secretions,
- • ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2), ratio (P/F ratio)\<80,
- • major lung surgery within prior 30 days.
- Inclusion Criteria healthcare providers included:
- • healthcare providers working in units (CCU and CCMU) as part of routine clinical care.
- Exclusion Criteria healthcare providers included:
- • healthcare providers that are not as part of routine care in CCU and CCMU
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Owen Albin, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials